Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 30;24(19):14800.
doi: 10.3390/ijms241914800.

Mesenchymal Stem Cells in the Treatment of COVID-19

Bei-Cyuan Guo  1 , Kang-Hsi Wu  2   3 , Chun-Yu Chen  4   5 , Wen-Ya Lin  6 , Yu-Jun Chang  7 , Tai-An Lee  8 , Mao-Jen Lin  9   10 , Han-Ping Wu  11   12
Affiliations
Review

Mesenchymal Stem Cells in the Treatment of COVID-19

Bei-Cyuan Guo et al. Int J Mol Sci. .

Abstract

Since the emergence of the coronavirus disease 2019 (COVID-19) pandemic, many lives have been tragically lost to severe infections. The COVID-19 impact extends beyond the respiratory system, affecting various organs and functions. In severe cases, it can progress to acute respiratory distress syndrome (ARDS) and multi-organ failure, often fueled by an excessive immune response known as a cytokine storm. Mesenchymal stem cells (MSCs) have considerable potential because they can mitigate inflammation, modulate immune responses, and promote tissue regeneration. Accumulating evidence underscores the efficacy and safety of MSCs in treating severe COVID-19 and ARDS. Nonetheless, critical aspects, such as optimal routes of MSC administration, appropriate dosage, treatment intervals, management of extrapulmonary complications, and potential pediatric applications, warrant further exploration. These research avenues hold promise for enriching our understanding and refining the application of MSCs in confronting the multifaceted challenges posed by COVID-19.

Keywords: COVID-19; mesenchymal stem cell; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Muralidar S., Ambi S.V., Sekaran S., Krishnan U.M. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. doi: 10.1016/j.biochi.2020.09.018. - DOI - PMC - PubMed
    1. Clemente-Suárez V.J., Navarro-Jiménez E., Moreno-Luna L., Saavedra-Serrano M.C., Jimenez M., Simón J.A., Tornero-Aguilera J.F. The impact of the COVID-19 pandemic on social, health, and economy. Sustainability. 2021;13:6314. doi: 10.3390/su13116314. - DOI
    1. WHO Coronavirus (COVID-19) Dashboard. [(accessed on 13 September 2023)]. Available online: https://covid19.who.int.
    1. Herby J., Jonung L., Hanke S. A literature review and meta-analysis of the effects of lockdowns on covid-19 mortality-II. 2022. Stud. Appl. Econ. 2022;200
    1. Zhao X., Liu S., Yin Y., Zhang T., Chen Q. Airborne transmission of COVID-19 virus in enclosed spaces: An overview of research methods. Indoor Air. 2022;32:e13056. doi: 10.1111/ina.13056. - DOI - PMC - PubMed